Here are the 10-K annual reports from POLOMAR HEALTH SVCS INC (PMHS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow PMHS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PMHS filings page.
Polomar Health Services, Inc. files its annual report describing a development-stage specialty compounding pharmacy focused on GLP-1 weight-loss drugs, erectile dysfunction treatments and future inhaled formulations. The company reports substantial operating losses, limited operating history and insufficient capital, raising doubt about its ability to continue as a going concern.
Polomar relies on telehealth partners and its own planned SlimRx online platform, with key product launches pushed into late 2026 and a major marketing partner suspending sales and seeking to terminate a distribution agreement. A planned merger with Altanine would shift roughly 80% of future equity to Altanine holders and further dilute existing shareholders.